β-微管蛋白Ⅰ基因突变与多烯紫杉醇治疗晚期非小细胞肺癌耐药的相关性研究

Association between classⅠβ-tubulin gene mutation and drug resistance of docetaxel in the treatment of advanced non-small cell lung cancer

摘要:

目的：探讨β-微管蛋白Ⅰ编码基因TUBB基因的突变与多烯紫杉醇治疗非小细胞肺癌（non-small cell lung cancer，NSCLC）耐药是否具有相关性。方法：用聚合酶链反应（polymerase chain reaction，PCR）和核苷酸测序技术检测90例晚期NSCLC患者TUBB基因是否存在突变。结果：36例患者在TUBB第4号外显子的第147号氨基酸编码序列处出现点突变，但这一突变与患者化疗疗效无明显相关。结论：β-微管蛋白Ⅰ的编码基因TUBB第4号外显子的第147号氨基酸编码序列的改变与多烯紫杉醇治疗NSCLC耐药无明显相关，但在患者中观察到了TUBB基因新的突变形式，该突变是否会对微管蛋白的结构和功能产生影响尚不确定，还需进一步深入研究。

Abstract:

Objective：To investigate the association between the mutation of the encoding gene of class Ⅰ?茁-tubulin （TUBB） and the drug resistance of docetaxel in the treatment of non-small cell lung cancer（NSCLC）. Methods：Polymerase chain reaction（PCR） and nucleotide sequencing were used to test whether mutation existed in 90 advanced NSCLC patients. Results：A mutation at the fourth ex－on of TUBB encoding sequence which encoding the 147th amino acid was found in 36 patients，but it was not significantly associated with the chemotherapy effect of decetaxel treatment for NSCLC. Conclusions：Mutation at the fourth exon of TUBB gene is not asso－ciated with the resistance of decetaxel treatment for NSCLC patients. Further investigation should be done to verify whether the struc－ture and function of tubulin would be affected by this mutation.